Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine
Schizophrenia Research · 2024
DOI: 10.1016/j.schres.2024.06.047 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Research, 2024. Verfasst von Petros Drosos und 6 weiteren Autor:innen. Beteiligte Einrichtung: NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen 5036, Norway; Department of Clinical Medicine, University of Bergen, Bergen 50…. Hauptthemen laut MEDLINE: Aripiprazole, Amisulpride, Olanzapine, Antipsychotic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway, Western Norway Regional Health Trust.
Abstract (Originalsprache)
Schizophrenia is a serious mental disorder, and monitoring remission is a widely used measure of effectiveness of the treatment provided. It is very important to identify possible factors correlating with remission. In our substudy of BeSt InTro, a randomized controlled trial of three antipsychotic drugs, 126 patients with ICD-10 diagnoses F20-29 (F23 excluded) were randomized to one of the second-generation antipsychotic drugs amisulpride, aripiprazole or olanzapine. Remission rate was calculated at seven assessment points, with and without using the time criterion of six months included in the consensus remission criteria. Because of drop-out (n = 77), we had data for 49 patients at one-year follow-up. These data were used to calculate the one-year remission rate to 55 % (27/49), without taking into consideration the 6-month time criterion. When we applied the consensus remission criteria with the 6-month time criterion included, the one-year remission rate was calculated for 59 patients: 29 % (17/59). Antipsychotic drug naivety and low negative symptom load at baseline correlated highly with belonging to the remission group. Use of amisulpride was more probable to lead to remission than that of aripiprazole, but it was not more probable than the use of olanzapine (in per-protocol analyses). Negative symptoms showed the largest resistance to treatment. The lack of remission for the majority of the participants in this closely monitored antipsychotic drug trial is alarming and could act as a reminder that novel treatment principles are needed, especially targeted towards the negative symptoms in schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen 5036, Norway; Department of Clinical Medicine, University of Bergen, Bergen 5007, Norway; TIPS-Network for Clinical Research in Psychosis, Clinic Fo…
- NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen 5036, Norway; Department of Clinical Medicine, University of Bergen, Bergen 5007, Norway.
- NORMENT, Division of Psychiatry, Haukeland University Hospital, Bergen 5036, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen 5007, Norway; TIPS-Network for Clinical Research in Psychosis, Clinic For Adult Mental Health, Stavanger University Hospital, Stavanger 4011, Norway.
- Institute for Mental Health, St Olav's University Hospital, Trondheim 7030, Norway; Department of Mental Health, Norwegian University of Natural Science and Technology, Trondheim 7491, Norway.
- Department of Psychiatry and Psychotherapy, Medical University Innsbruck, Innsbruck 6020, Austria.
Förderung
- Research Council of Norway
- Western Norway Regional Health Trust
Zitieren
APA
Drosos, P., Johnsen, E., Bartz-Johannessen, C. A., Larsen, T. K., Reitan, S. K., Rettenbacher, M., & Kroken, R. A. (2024). Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine. Schizophrenia Research. https://doi.org/10.1016/j.schres.2024.06.047
Vancouver
Drosos P, Johnsen E, Bartz-Johannessen CA, Larsen TK, Reitan SK, Rettenbacher M, et al. Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine. Schizophrenia Research. 2024. doi:10.1016/j.schres.2024.06.047
BibTeX
@article{Drosos2024,
author = {Drosos, Petros and Johnsen, Erik and Bartz-Johannessen, Christoffer Andreas and Larsen, Tor Ketil and Reitan, Solveig Klæbo and Rettenbacher, Maria and Kroken, Rune Andreas},
title = {Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine},
journal = {Schizophrenia Research},
year = {2024},
doi = {10.1016/j.schres.2024.06.047}
}
EUVIMED